GlaxoSmithKline (LON:GSK) Receives Hold Rating from Shore Capital
Shore Capital reissued their hold rating on shares of GlaxoSmithKline (LON:GSK) in a research report released on Wednesday morning, ThisIsMoney.Co.Uk reports.
Several other equities research analysts have also recently issued reports on the stock. Liberum Capital reiterated a hold rating on shares of Daily Mail and General Trust P L C in a research report on Tuesday, July 2nd. HSBC set a €16.50 ($19.19) price objective on shares of UniCredit and gave the company a buy rating in a research report on Tuesday, May 14th. Deutsche Bank reiterated a buy rating and set a $80.00 price objective on shares of Bayerische Motoren Werke in a research report on Monday. Morgan Stanley initiated coverage on shares of in a research report on Monday, June 17th. They issued an equal weight rating and a GBX 215 ($2.81) price target on the stock. Finally, Goldman Sachs Group set a $13.00 price target on shares of Ford Motor and gave the stock a buy rating in a research report on Thursday, June 13th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of GBX 1,535.88 ($20.07).
Shares of GlaxoSmithKline stock traded down GBX 10.80 ($0.14) on Wednesday, hitting GBX 1,632.40 ($21.33). 7,804,311 shares of the company traded hands, compared to its average volume of 9,120,000. The firm has a market cap of $81.44 billion and a PE ratio of 20.79. The company has a quick ratio of 0.45, a current ratio of 0.72 and a debt-to-equity ratio of 942.07. GlaxoSmithKline has a 52 week low of GBX 1,408.80 ($18.41) and a 52 week high of GBX 1,651 ($21.57). The company’s 50-day moving average price is GBX 1,583.69.
In other news, insider Manvinder Singh Banga acquired 458 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was bought at an average cost of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82). Insiders have acquired 482 shares of company stock valued at $755,935 over the last ninety days.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading: What is insider trading?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.